CMC– tag –
-
Bonus Track Special: Implications for Japan & Asia — How US “Reallocation” Reshapes Opportunities
Category: Pharma & Biotech NEWS | Special Feature B Key Takeaways Capital follows the cleared path (POC → CMC → access): US selectivity raises the bar for Asia-origin programs on speed, manufacturability, and reimbursement narrative.... -
Bonus Track-Special: Redesigning M&A & Partnerships — From Overlap Removal to “Rights Architecture”
Category: Pharma & Biotech NEWS | Special Feature A Key Takeaways PMI defines value: 80% of deal value crystallizes within 90–180 days post-close through speed and transparency; eliminate overlaps with KPI governance. Rights redesign... -
Series “Reading 2025 Layoffs”: Modality-by-Modality: Manufacturing, Regulatory, and Commercial Realities (Part 3)
Category: Pharma & Biotech NEWS | Series “Reading 2025 Layoffs” — Part 3 Key Takeaways The “capital-efficiency equation” is modality-specific: even with similar P2 wins, cell/gene/RNA/antibody–degrader programs require very different...
1